[1] FURTADO RHM, BONACA MP, RAZ I, et al.Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction[J]. Circulation, 2019, 139(22): 2516-2527. [2] KAISANLAHTI A, GLUMOFF T, et al.Browning of white fat: agents and implications for beige adipose tissue to type 2 diabetes[J]. Journal of Physiology and Biochemistry, 2019, 75(1): 1-10. [3] RODRÍGUEZ A, CATALÁN V, RAMÍREZ B, et al. Impact of adipokines and myokines on fat browning[J]. Journal of Physiology and Biochemistry, 2020, 76(2): 227-240. [4] CUI M, GAO Y, ZHAO Y, et al.Association between adiponectin gene polymorphism and environmental risk factors of type 2 diabetes mellitus among the Chinese population in hohhot[J]. BioMed research international, 2020(6): 6383906. [5] LI S, SHIN HJ, DING EL, et al.Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis[J]. JAMA, 2009, 302(2): 179-188. [6] YANAI H, YOSHIDA H.Beneficial effects of adiponectin on glucose and lipid metabolism and atherosclerotic progression: mechanisms and perspectives[J]. International Journal of Molecular Sciences, 2019, 20(5): 1190 [7] DEFRONZO RA, INZUCCHI S, ABDUL-GHANI M, et al.Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes[J]. Diabetes & Vascular Disease Research, 2019, 16(2): 133-143. [8] Cochrane. Cochrane Handbook for Systematic Reviews of Interventions[EB/OL].[2022-08-01]. https://training.cochrane.org/handbook. [9] GASTALDELLI A, MIYAZAKI Y, MAHANKALI A, et al.The effect of pioglitazone on the liver: role of adiponectin[J]. Diabetes Care, 2006, 29(10): 2275-2281. [10] HANEFELD M, PFUTZNER A, FORST T, et al.Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study[J]. Cardiovascular Diabetology, 2011, 10: 65. [11] KAKU K.Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial[J]. Current Medical Research and Opinion, 2009, 25(5): 1111-1119. [12] ERDEM G, DOGRU T, TASCI I, et al.The effects of pioglitazone and metformin on plasma visfatin levels in patients with treatment naive type 2 diabetes mellitus[J]. Diabetes Research and Clinical Practice, 2008, 82(2): 214-218. [13] ESPOSITO K, MAIORINO MI, PALO CI, et al.Effects of pioglitazone versus metformin on circulating endothelial microparticles and progenitor cells in patients with newly diagnosed type 2 diabetes--a randomized controlled trial[J]. Diabetes, Obesity & Metabolism, 2011, 13(5): 439-445. [14] NISHIO K, SAKURAI M, KUSUYAMA T, et al.A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes[J]. Diabetes Care, 2006, 29(1): 101-106. [15] OZ O, TUNCEL E, ERYILMAZ S, et al.Arterial elasticity and plasma levels of adiponectin and leptin in type 2 diabetic patients treated with thiazolidinediones[J]. Endocrine, 2008, 33(1): 101-105. [16] PFUTZNER A, SCHONDORF T, TSCHOPE D, et al.PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia[J]. Diabetes Technology & Therapeutics, 2011, 13(6): 637-643. [17] SHARMA PK, BHANSALI A, SIALY R, et al.Effects of pioglitazone and metformin on plasma adiponectin in newly detected type 2 diabetes mellitus[J]. Clinical Endocrinology, 2006, 65(6): 722-728. [18] HE XL, LIU J, ZHANG HX.et al.Comparison of therapeutic effects of pioglitazone and acarbose on elderly patients with type 2 diabetes mellitus and hypertension[J]. Chinese Journal of Multiple Organ Diseases in the Elderly(中华老年多器官疾病杂志), 2014, 13(12): 907-912. [19] KADOWAKI T, YAMAUCHI T, KUBOTA N, et al.Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome[J]. The Journal of Clinical Investigation, 2006, 116(7): 1784-1792. [20] YU Y, DU H, WEI S, et al.Adipocyte-derived exosomal MiR-27a induces insulin resistance in skeletal muscle through repression of PPARγ[J]. Theranostics, 2018, 8(8): 2171-2188. [21] ACHARI AE, JAIN SK.Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction[J]. International Journal of Molecular Sciences, 2017, 18(6): 1321. [22] ÖZAY Y, OZEK D, YILDIRIM F, et al.The effect of diabetes on vitreous levels of adiponectin and inflammatory cytokines in experimental rat model[J]. Advances in Clinical and Experimental Medicine : Official Organ Wroclaw Medical University, 2020, 29(4): 449-452. [23] FANG H, JUDD RL.Adiponectin regulation and function[J]. Comprehensive Physiology, 2018, 8(3): 1031-1063. [24] LEBOVITZ HE.Thiazolidinediones: the forgotten diabetes medications[J]. Current Diabetes Reports, 2019, 19(12): 151. [25] MARECHAL L, LAVIOLETTE M, RODRIGUE-WAY A, et al.The CD36-PPARγ pathway in metabolic disorders[J]. International Journal of Molecular Sciences, 2018, 19(5) : 1529. [26] ASTAPOVA O, LEFF T.Adiponectin and PPARγ: cooperative and interdependent actions of two key regulators of metabolism[J]. Vitamins and Hormones, 2012, 90: 143-162. [27] PEREIRA RI, LEITNER JW, ERICKSON C et al. Pioglitazone acutely stimulates adiponectin secretion from mouse and human adipocytes via activation of the phosphatidylinositol 3’-kinase[J]. Life Sciences, 2008, 83(19-20): 638-643. |